Edwards Lifesciences Corporation (NYSE:EW) Shares Acquired by Teacher Retirement System of Texas

Teacher Retirement System of Texas grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 196.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,358 shares of the medical research company's stock after purchasing an additional 69,825 shares during the period. Teacher Retirement System of Texas' holdings in Edwards Lifesciences were worth $7,636,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Crowley Wealth Management Inc. purchased a new position in Edwards Lifesciences in the 4th quarter worth $26,000. Vega Investment Solutions purchased a new position in Edwards Lifesciences in the 4th quarter worth $27,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences in the 4th quarter worth $29,000. Global X Japan Co. Ltd. raised its stake in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC grew its position in Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after purchasing an additional 205 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 0.3%

NYSE EW traded down $0.24 on Tuesday, reaching $76.45. The stock had a trading volume of 988,605 shares, compared to its average volume of 5,226,216. The stock has a fifty day moving average price of $76.14 and a two-hundred day moving average price of $73.29. The firm has a market capitalization of $44.85 billion, a price-to-earnings ratio of 10.92, a P/E/G ratio of 3.86 and a beta of 1.11. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $58.93 and a 12-month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The company's revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.66 earnings per share. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of the company's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the transaction, the vice president owned 33,496 shares in the company, valued at $2,514,879.68. This represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $69.81, for a total transaction of $663,195.00. Following the completion of the transaction, the vice president owned 47,206 shares of the company's stock, valued at $3,295,450.86. This represents a 16.75% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,348 shares of company stock valued at $2,977,683. Insiders own 0.34% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the topic of several analyst reports. Truist Financial cut their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Robert W. Baird increased their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. Piper Sandler lifted their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. Finally, Evercore ISI lifted their price target on Edwards Lifesciences from $73.00 to $77.00 and gave the company an "in-line" rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of "Hold" and a consensus target price of $80.40.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.